Cognitive-Behavioral Approaches for the Treatment of Substance Use Disorders and Co-occurring Mental Health Conditions

Substance use disorders (SUD) are prevalent, complex medical conditions. Individuals with SUD vary considerably in clinical severity, accompanying medical sequelae, degree of functional impairment, often struggle with comorbid psychiatric conditions. Cognitive-behavioral therapies for individuals with SUD and co-occurring mental health conditions have shown to be effective in reducing psychopathology and substance use and increasing the chances of remission. This chapter highlights three CBT-based interventions for this patient population: Dialectical Behavior Therapy; Acceptance and Commitment Therapy; and Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE) and provides an illustrative case example for each treatment approach to demonstrate how to implement each intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic €32.70 /Month

Buy Now

Price includes VAT (France)

eBook EUR 117.69 Price includes VAT (France)

Hardcover Book EUR 116.04 Price includes VAT (France)

Tax calculation will be finalised at checkout

Purchases are for personal use only

References

  1. Schuckit MA. An overview of genetic influences in alcoholism. J Subst Abus Treat. 2009;36:S5–14. Google Scholar
  2. Urbanoski KA, Kelly JF. Understanding genetic risk for substance use and addiction: a guide for non-geneticists. Clin Psychol Rev. 2012;32(1):60–70. https://doi.org/10.1016/j.cpr.2011.11.002. ArticlePubMedGoogle Scholar
  3. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2020. Retrieved from https://www.samhsa.gov/data/. Google Scholar
  4. Johnson RA, Gerstein DR. Initiation of use of alcohol, cigarettes, marijuana, cocaine, and other substances in US birth cohorts since 1919. Am J Publ Health. 1998;88(1):27–33. https://doi.org/10.2105/AJPH.88.1.27. ArticleCASGoogle Scholar
  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: Author; 2013. BookGoogle Scholar
  6. Substance Abuse and Mental Health Services Administration. Results from the 2012 national survey on drug use and health: summary of national findings, NSDUH series H-46, HHS publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013. Google Scholar
  7. Han B, Compton WM, Blanco C, Colpe LJ. Prevalence, treatment, and unmet treatment needs of US adults with mental health and substance use disorders. Health Aff. 2017;36(10):1739–47. https://doi.org/10.1377/hlthaff.2017.0584. ArticleGoogle Scholar
  8. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807–16. https://doi.org/10.1001/archpsyc.61.8.807. ArticlePubMedGoogle Scholar
  9. Mills KL, Teesson M, Ross J, Peters L. Trauma, PTSD, and substance use disorders: findings from the Australian National Survey of Mental Health and Well-Being. Am J Psychiatry. 2006;163(4):652–8. https://doi.org/10.1176/appi.ajp.163.4.652. ArticlePubMedGoogle Scholar
  10. Trull TJ, Jahng S, Tomko RL, Wood PK, Sher KJ. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Personal Disord. 2010;24(4):412–26. https://doi.org/10.1521/pedi.2010.24.4.412. ArticleGoogle Scholar
  11. Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, Bierut LJ, Pato MT. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014;71(3):248–54. https://doi.org/10.1001/jamapsychiatry.2013.3726. ArticlePubMedPubMed CentralGoogle Scholar
  12. Adamson SJ, Sellman JD, Frampton CM. Patient predictors of alcohol treatment outcome: a systematic review. J Subst Abus Treat. 2009;36(1):75–86. https://doi.org/10.1016/j.jsat.2008.05.007. ArticleGoogle Scholar
  13. Kodl MM, Fu SS, Willenbring ML, Gravely A, Nelson DB, Joseph AM. (2008). The impact of depressive symptoms on alcohol and cigarette consumption following treatment for alcohol and nicotine dependence. Alcohol Clin Exp Res. 2008;32(1):92–9. https://doi.org/10.1111/j.1530-0277.2007.00556. ArticlePubMedGoogle Scholar
  14. Krawczyk N, Feder KA, Saloner B, Crum RM, Kealhofer M, Mojtabai R. The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample. Drug Alcohol Depend. 2017;175:157–63. https://doi.org/10.1016/j.drugalcdep.2017.02.006. ArticlePubMedPubMed CentralGoogle Scholar
  15. Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harvard Rev Psychiat. 1997;4(5):231–44. https://doi.org/10.3109/10673229709030550. ArticleCASGoogle Scholar
  16. American Psychiatric Association. Substance-related and addictive disorders. In: Diagnostic and statistical manual of mental disorders, 5th ed. 2013. Google Scholar
  17. Nickerson A, Barnes JB, Creamer M, et al. The temporal relationship between posttraumatic stress disorder and problem alcohol use following traumatic injury. J Abnorm Psychol. 2014;123(4):821–34. https://doi.org/10.1037/a0037920. ArticlePubMedGoogle Scholar
  18. Read JP, Wardell JD, Colder CR. Reciprocal associations between PTSD symptoms and alcohol involvement in college: a three-year trait-state-error analysis. J Abnorm Psychol. 2013;122(4):984–97. https://doi.org/10.1037/a0034918. ArticlePubMedPubMed CentralGoogle Scholar
  19. Linehan MM. Cognitive-behavioral treatment of borderline personality disorder. New York: Guilford Press; 1993. Google Scholar
  20. Linehan MM, Schmidt H, Dimeff LA, Craft JC, Kanter J, Comtois KA. Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict. 1999;8:279–92. https://doi.org/10.1080/105504999305686. ArticleCASPubMedGoogle Scholar
  21. Dimeff L, Rizvi SL, Brown M, Linehan MM. Dialectical behavior therapy for substance abuse: a pilot application to methamphetamine-dependent women with borderline personality disorder. Cogn Behav Pract. 2000;2000(7):457–68. https://doi.org/10.1016/S1077-7229(00)80057-7. ArticleGoogle Scholar
  22. Linehan MM, Dimeff LA, Reynolds SK, Comtois KA, Welch SS, Heagerty P. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend. 2002;37:13–26. https://doi.org/10.1016/s0376-8716(02)00011-x. ArticleGoogle Scholar
  23. Maffei C, Cavicchiolo M, Movalli M, Cavallaro R, Fossati A. Dialectical behavior therapy skills training in alcohol dependence treatment: findings based on an open trial. Subst Use Misuse. 2018;53(14):2368–85. https://doi.org/10.1080/10826084.2018.1480035. ArticlePubMedGoogle Scholar
  24. Flynn D, Joyce M, Spillane A, Wrigley C, Corcoran P, Hayes A, Flynn M, Wyse D, Corkery B, Mooney B. Does an adapted dialectical behavior therapy skills training programme result in positive outcomes for participants with a dual diagnosis? A mixed methods study. Addict Sci Clin Pract. 2019;14(1):28–38. https://doi.org/10.1186/s13722-019-0156-2. ArticlePubMedPubMed CentralGoogle Scholar
  25. Linehan MM. Skills training manual for treating borderline personality disorder. New York: Guilford Press; 1993. Google Scholar
  26. Linehan MM. DBT skills training manual. 2nd ed. New York: Guilford Press; 2015. Google Scholar
  27. Gratz KL, Roemer L. Multidimensional assessment of emotion regulation and dysregulation: development, factor structure, and initial validation of the difficulties in emotion regulation scale. J Psychopathol Behav Assess. 2004;26(1):41–54. https://doi.org/10.1023/B:JOBA.0000007455.08539.94. ArticleGoogle Scholar
  28. Bohlmeijer E, ten Klooster PM, Fledderus M, Veehof M, Baer R. Psychometric properties of the five facet mindfulness questionnaire in depressed adults and development of a short form. Assessment. 2011;8(3):308–20. https://doi.org/10.1177/1073191111408231. ArticleGoogle Scholar
  29. Neacsiu AD, Rizvi SL, Vitaliano PP, Lynch TR, Linehan MM. The dialectical behavior therapy ways of coping checklist: development and psychometric properties. J Clin Psychol. 2010;66(6):563–82. https://doi.org/10.1002/jclp.20685. ArticlePubMedGoogle Scholar
  30. Marlatt GA, Witkiewitz K, Dillworth TM, Bowen S, Parks GA, MacPherson LM, et al. Vipassana meditation as a treatment for alcohol and drug use disorders. In: Hayes SC, Follette VM, Linehan MM, editors. Mindfulness and acceptance: expanding the cognitive-behavioral tradition. New York: Guildford Press; 2004. p. 261–87. Google Scholar
  31. Marlatt GA, Larimer ME, Witkiewitz K. Harm reduction: pragmatic strategies for managing high-risk behaviors. 2nd ed. New York: Guilford Press; 2012. Google Scholar
  32. Hayes SC, Strosahl KD, Wilson KG. Acceptance and commitment therapy: the process and practice of mindful change (2nd edition). New York: The Guilford Press; 2012. BookGoogle Scholar
  33. Francis AW, Dawson DL, Golijani-Moghaddam N. The development and validation of the Comprehensive assessment of Acceptance and Commitment Therapy processes (CompACT). J Contextual Behav Sci. 2016;5(3):134–45. https://doi.org/10.1016/j.jcbs.2016.05.003. ArticleGoogle Scholar
  34. Lee EB, An W, Levin ME, Twohig MP. An initial meta-analysis of Acceptance and Commitment Therapy for treating substance use disorders. Drug Alcohol Depend. 2015;155:1–7. https://doi.org/10.1016/j.drugalcdep.2015.08.004. ArticlePubMedGoogle Scholar
  35. Gloster AT, Walder N, Levin ME, Twohig MP, Karekla M. The empirical status of acceptance and commitment therapy: a review of meta-analyses. J Contextual Behav Sci. 2020;2020(18):181–92. https://doi.org/10.1016/j.jcbs.2020.09.009. ArticleGoogle Scholar
  36. Harris R. ACT made simple: an easy-to-read primer on acceptance and commitment therapy. 2nd ed. Oakland, CA: New Harbinger Publications; 2019. Google Scholar
  37. Luoma JB, Hayes SC, Walser RD. Learning ACT: an acceptance and commitment therapy skills training manual for therapists. 2nd ed. Oakland, CA: New Harbinger Publications; 2017. Google Scholar
  38. Polk KL, Schoendorff B, Webster M, Olaz FO. The essential guide to the ACT matrix: a step-by-step approach to using the ACT matrix model in clinical practice. Oakland, CA: New Harbinger Publications; 2016. Google Scholar
  39. Foa EB, Yusko DA, McLean CP, Suvak MK, Bux DA, Oslin D, Volpicelli J. Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. JAMA. 2013;310:488–95. https://doi.org/10.1001/jama.2013.8268. ArticleCASPubMedGoogle Scholar
  40. Smout MF. Psychotherapy for methamphetamine dependence: a treatment manual. Adelaide: Drug and Alcohol Services South Australia; 2008. Google Scholar
  41. Luoma JB, Platt MG. Shame, self-criticism, self-stigma, and compassion in acceptance and commitment therapy. Curr Opin Psychol. 2015;2:97–101. https://doi.org/10.1016/j.copsyc.2014.12.016. ArticleGoogle Scholar
  42. Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull. 1986;99(1):20–35. https://doi.org/10.1037/0033-2909.99.1.20. ArticleCASPubMedGoogle Scholar
  43. Back SE, Foa EB, Killeen TK, Mills KL, Teesson M, Cotton BD, Carroll KM, Brady KT. Treatments that work. Concurrent treatment of PTSD and substance use disorders using prolonged exposure (COPE): therapist guide. Oxford University Press; 2015. BookGoogle Scholar
  44. Foa EB, McLean CP, Zang Y, Zong J, Rauch S, Porter K, Kauffman B. Psychometric properties of the Posttraumatic Stress Disorder Symptoms Scale Interview for DSM-5 (PSSI-5). Psychol Assess. 2016;28:1159–65. https://doi.org/10.1037/pas0000259. ArticlePubMedGoogle Scholar
  45. Weathers FW, Blake DD, Schnurr PP, Kaloupek DG, Marx BP, Keane TM. The clinician-administered PTSD scale for DSM-5 (CAPS-5). 2013. Available from www.ptsd.va.gov.
  46. Foa EB, Ehlers A, Clark DM, Tolin DF, Orsillo SM. The Posttraumatic Cognitions Inventory (PTCI): development and validation. Psychol Assess. 1999;11(3):303–14. https://doi.org/10.1037/1040-3590.11.3.303. ArticleGoogle Scholar
  47. Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The PTSD checklist for DSM-5 (PCL-5). 2013. Available from www.ptsd.va.gov.
  48. van Minnen A, Harned MS, Zoellner L, Mills K. Examining potential contraindications for prolonged exposure therapy for PTSD. Eur J Psychotraumatol. 2012;2012(3):1880. https://doi.org/10.3402/ejpt.v3i0.18805. ArticleGoogle Scholar
  49. Herman JL. Trauma and recovery: the aftermath of violence - from domestic abuse to political power. Basic Books; 1992. Google Scholar
  50. Najavits LM. The problem of dropout from “gold standard” PTSD therapies. F1000Prime Rep. 2015;7:43. https://doi.org/10.12703/P7-43. ArticleCASPubMedPubMed CentralGoogle Scholar

Author information

Authors and Affiliations

  1. Department of Psychiatry, Behavioral Medicine Program, Massachusetts General Hospital, Boston, MA, USA Allison K. Labbe
  2. Private Practice, Newton, MA, USA Daniel P. Johnson
  3. Department of Psychiatry, West End Clinic, Massachusetts General Hospital, Boston, MA, USA Toby Lynch
  4. Clinical Psychology Department, William James College, Newton, MA, USA Julie D. Yeterian
  5. Department of Psychiatry, Center for Addiction Medicine, Massachusetts General Hospital, Boston, MA, USA John F. Kelly
  1. Allison K. Labbe